The role of increased prolactin levels under gnrh analogue treatment in advanced prostatic carcinoma

Matzkin, Haim; Kaver, Issac; Lewyshon, Orly; Ayalon, Daniel; Braf, Z

doi:10.1002/1097-0142(19880601)61:11<2187::aid-cncr2820611109>3.0.co;2-7

Cited by 13 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, to date no consistent demonstration of the role of human PRL in prostatic disease (15,16) or even in normal prostate function has been presented.…”

mentioning

confidence: 99%

Prolactin and Prostate Hypertrophy: A Pilot Observational, Prospective, Case-Control Study in Men with Prolactinoma

Colao¹,

Vitale²,

Sarno³

et al. 2004

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

In experimental models, prolactin (PRL) displays independent hypertrophic effects on the prostate. To investigate whether hyperprolactinemia is associated with prostate enlargement in humans, we designed this open, prospective, case-control study enrolling 20 men with prolactinoma (aged 34 +/- 10 yr) and 20 age-matched healthy men. The endocrine profile and prostate transrectal ultrasonography were performed before and after 12 and 24 months of cabergoline treatment in the patients and at study entry and after 24 months in the controls. The patients had lower serum testosterone, dihydrotestosterone (DHT), and IGF-I levels and prostate volume (15.4 +/- 3.5 vs. 19.6 +/- 5.1 ml; P < 0.001) and higher PRL levels and prostate-specific antigen density than controls. There was no difference in prostate and transitional zone volumes between patients with normoandrogenemia (n = 8) or hypoandrogenemia (n = 12). After 12 and 24 months of treatment, PRL, testosterone, and DHT levels were normal in all cases, as were IGF-I and IGF-binding protein-3 levels. After 24 months, prostate volume was comparable to that in controls (21.7 +/- 4.5 vs. 22.5 +/- 4.7 ml). There were no changes in prostate structure throughout the study period in either the patients or the controls. In conclusion, in young men with prolactinoma PRL excess is unlikely to have effects on the prostate per se, because it is accompanied by low testosterone and DHT levels that produce the major effects.

show abstract

“…In contrast, to date no consistent demonstration of the role of human PRL in prostatic disease (15,16) or even in normal prostate function has been presented.…”

mentioning

confidence: 99%

Prolactin and Prostate Hypertrophy: A Pilot Observational, Prospective, Case-Control Study in Men with Prolactinoma

Colao¹,

Vitale²,

Sarno³

et al. 2004

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

show abstract

“…The prolonged administration of BUS blocks gonadotropin release and thereby achieves the effective suppression of gonadal steroidogenesis [7]. There is no uniform opinion in the relevant literature as concerns the possible changes in prolactin (PRL) secretion following BUS treatment: unchanged or decreased [10,11] and increased [12] PRL levels have all been observed. The various changes in PRL secretion following BUS treatment may be explained by differences in individual sensitivity, in the doses of BUS applied, in the duration of treatment, etc.…”

Section: Introductionmentioning

confidence: 99%

Combined Treatment with Buserelin+Cabergoline in Patient with Prostate Cancer and Pituitary Macroprolactinoma

Gervain¹,

Vörös²,

Andor³

et al. 2010

JCT

View full text Add to dashboard Cite

Twelve years following hemicolectomy for colon adenocarcinoma, a 75-year-old patient with prostate cancer was treated for 4 weeks with the antiandrogen nilutamide and then with the long-acting GnRH agonist buserelin. The serum testosterone and prostate-specific antigen levels had decreased dramatically after 3 months of treatment. After 2 years of buserelin administration, the hormonal state was examined. Serum estradiol, testosterone, DHEA, DHEAS, FSH and LH levels proved to be suppressed, but the serum PRL concentration was extremely high (3 365 mIU/l). The pituitary MRI revealed a macroadenoma. The patient was treated with the dopamine agonist cabergoline, together with buserelin. After 9 months of this combined treatment, the prostate-specific antigen and testosterone levels were very low; the serum estradiol, DHEA, DHEAS, FSH and LH concentrations remained suppressed. The serum PRL level fell dramatically to 6.95 mIU/l, and a significant reduction in tumor size was observed on MRI. In conclusion: Combined buserelin + cabergoline treatment proved a highly successful procedure to cure this patient with prostate carcinoma and subsequent pituitary macroprolactinoma

show abstract

Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot lhrh analogue

Mahler

Verhelst

Chaban

et al. 1991

Cancer

View full text Add to dashboard Cite

Sixty patients with advanced prostatic carcinoma were treated with monthly subcutaneous injections of a depot formulation of goserelin, a luteinizing hormone-releasing hormone (LHRH) analogue (Zoladex, ICI Pharma, Destelbergen, Belgium). All patients were regularly evaluated with measurements of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), and prolactin (PRL) levels. In 15 patients among them who could be treated for more than 42 months, an LHRH stimulation test was performed at the end of each 28-day period and before the next administration of the depot formulation. A complete and maintained suppression of both T and LH levels was seen. FSH levels also decreased, but to a lesser extent than LH levels, and showed a small escape after reaching a minimum value after 1 month of therapy. The LHRH challenge after 42 months of therapy elicited no significant responses of LH and FSH levels. The PRL values showed a small decrease.

show abstract

The role of increased prolactin levels under gnrh analogue treatment in advanced prostatic carcinoma

Cited by 13 publications

References 23 publications

Prolactin and Prostate Hypertrophy: A Pilot Observational, Prospective, Case-Control Study in Men with Prolactinoma

Prolactin and Prostate Hypertrophy: A Pilot Observational, Prospective, Case-Control Study in Men with Prolactinoma

Combined Treatment with Buserelin+Cabergoline in Patient with Prostate Cancer and Pituitary Macroprolactinoma

Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot lhrh analogue

Contact Info

Product

Resources

About